New 'peptoids' show promise in resistant prostate cancer

A new generation of anti-androgen drugs such as Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Zytiga have increased survival rates in metastatic castration-resistant prostate cancer (mCRPC). But a multidisciplinary research team from New York University wanted to improve the prospects for patients even more. So the scientists designed an entirely new type of drug compound, and they have produced some encouraging early study results.